Program Introduction

LAI antipsychotics are often initiated late in adults with schizophrenia, despite evidence supporting early use. Experts discuss the barriers to initiating LAI treatment, as well as adherence, efficacy and safety data.

Learning Objectives

After completing this educational activity, you should be able to:

• Examine data comparing the efficacy of LAIAs and oral medications.  
• Analyze the clinical trial data and unique considerations of available LAIAs.  
• Implement early integration of LAIA therapies in appropriate patients.  

Available Credit

Program Introduction

Mood disorders throughout women's reproductive stages require comprehensive care to alleviate unnecessary suffering, comorbidities, and unwanted outcomes.

Learning Objectives

After completing this educational activity, you should be able to:

• Appraise the influence of the reproductive stage on mood disorders and comorbid psychiatric conditions in women
• Assess factors involved in the diagnoses of mood disorders in women and the differential diagnoses and common comorbidities
• Summarize evidence-based approaches for diagnosing and treating mood disorders in women

Available Credit

• 1.00 AMA PRA Category 1 Credit™
• 1.00 Participation

Program Introduction

This educational activity, presented by Dr. Deligiannidis, Dr. Vega, and Dr. Smith, offers clinicians an essential update on perinatal depression (PND), including its pathophysiology, diagnosis, and treatment options. With a focus on the latest research and therapeutic advancements, this session highlights the significant impact of timely diagnosis and the risks of delayed intervention.

Participants will explore the neurobiological underpinnings of PND, including mechanisms such as altered GABAergic neurotransmission and the roles of neuroactive steroids like allopregnanolone. The presentation also reviews evidence-based approaches, covering both traditional antidepressants (SSRIs, SNRIs, TCAs) and innovative treatments like brexanolone and zuranolone. Practical insights on real-world applications, including considerations for the post-COVID era, provide clinicians with actionable knowledge to enhance care for patients affected by PND.

Learning Objectives

• Identify appropriate best practices for the diagnosis of PDP
• Implement evidence-based current therapies for patients with PDP

Available Credit

• 1.00 AMA PRA Category 1 Credit^TM
• 1.00 Participation

Program Introduction

Join us for a dynamic one-hour CME activity on Parkinson’s Disease Psychosis (PDP) with top experts Mark F. Lew, MD, and Jennifer Hui, MD. Unlock the latest best practices for diagnosing PDP and implementing cutting-edge therapies. The session kicks off with a deep dive into Parkinson’s Disease, covering its prevalence, motor and nonmotor symptoms, and the unique challenges of PDP. Next, master the intricacies of recognizing and diagnosing PDP with the newest diagnostic criteria and screening tools. Finally, conquer PDP treatment and management strategies, including behavioral approaches, medication adjustments, and safe antipsychotic options. Plus, gain invaluable insights from the caregiver of a real-world patient with PDP, providing a firsthand perspective on managing this complex condition. Boost your clinical expertise and transform patient care with this essential update on managing Parkinson’s Disease Psychosis.

Learning Objectives

• Identify appropriate best practices for the diagnosis of PDP
• Implement evidence-based current therapies for patients with PDP

Available Credit

• 1.00 AMA PRA Category 1 Credit^TM
• 1.00 Participation